The Detection Kit for Neutralization Antibody of SARS-CoV-2 (Competitive ELISA) has recently got the CE Mark. It was developed by BGI PathoGenesis Pharmaceutical Technology Co., Ltd., a subsidiary of BGI Genomics.
The positive conversion rate of neutralizing antibody is one of the important indicators for clinical research and vaccine efficacy monitoring to evaluate the level of effective antibodies generated after vaccination. BGI‘s new CE marked kit can detect the neutralizing antibody of SARS-CoV-2 in human serum or plasma samples after inoculation, helping to evaluate the positive conversion rate of a COVID-19 vaccine and providing scientific data support for the monitoring and evaluation of vaccines, and helps continuously optimize vaccine clinical research data.
Last month, BGI’s Rapid Identification Kit for B.1.1.7 lineage and B.1.351 lineage of SARS-CoV-2 (Fluorescence RT-PCR), and the Detection Kit for six mutations in S gene of SARS-CoV-2 (ARMS-PCR) also got the CE Mark.